Joseph Mikhael, MD, is a Professor at the Applied Cancer Research and Drug Discovery Division of the Translational Genomics Research Institute (TGen), Phoenix, AZ, an affiliate of the City of Hope Cancer Center. Prof. Mikhael is also the Chief Medical Officer of the International Myeloma Foundation (IMF), serves as a Councillor on the Executive Committee of the American Society of Hematology, and as Director of Myeloma Research and Consultant Hematologist at HonorHealth. Previously, Prof. Mikhael worked as a Hematologist at the Princess Margaret Hospital, Toronto, Ontario, Canada (2003 – 2008) and at the Mayo Clinic, Phoenix, AZ (2008 -2018).
Prof. Mikhael received his medical degree (1993-1997) from the University of Ottawa, Ottawa, Canada, where he also completed a residency in internal medicine (1997-2000). After that, he completed a residency in hematology (2000-2003) and a Master of education (2002-2004) at the University of Toronto, Toronto, Canada. He then completed a fellowship in multiple myeloma at the Princess Margaret Hospital, Toronto, Ontario, Canada (2003 – 2004).
Speaking on multiple myeloma
Prof. Mikhael’s clinical interest is in multiple myeloma and its related conditions, Waldenström’s macroglobulinemia and amyloidosis. He is the principal investigator of many clinical trials in both newly diagnosed and relapsed multiple myeloma. Prof. Mikhael developed the CD38 monoclonal antibody, isatuximab, used in the treatment of multiple myeloma. His other research interests lie in medical education, immune thrombocytopenia, thrombosis and pharmacoeconomic.